STAT19h
Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more
GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...
BioPharma Dive3d
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
Ineffective cough syrup ingredient should be axed officially, FDA says
The U.S. Food and Drug Administration has proposed removing oral phenylephrine, widely used in cold and cough syrups, as an active ingredient ... ingredient Companies such as Procter & Gamble and GSK ...
Vaccine makers exposed to political pathogen
It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...
STAT3d
Pharma giant GSK is quitting BIO in latest setback for the lobbying group
WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...
U.S. FDA proposes ending use of popular decongestant present in cold medicines
The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...
Le Lézard6d
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvotm
Syndax Pharmaceuticals and Royalty Pharma plc today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales ...